Dupixent CTCL MDL 3180: Build the Timeline Before Records Get Hard to Find
The Dupixent CTCL MDL is underway in New Jersey. Families should preserve prescription, dermatology, pathology, and oncology records now.
The Dupixent CTCL MDL is underway in New Jersey. Families should preserve prescription, dermatology, pathology, and oncology records now.
What patients and families should know after Dupixent CTCL claims were centralized in MDL No. 3180 in New Jersey.
A plain-English July 2026 update on Dupixent CTCL MDL 3180, what the JPML order says, and which records families should save now.
Mid-2026 is one of the busiest stretches in recent mass tort history: two new MDLs formed in a single week in June, the Supreme Court reshaped the Roundup litigation, and the FDA moved to withdraw an approved drug from the market. Here is where the major dockets stand as of July 7, 2026. New MDLs:…
What families should know about Dupixent lawsuit reviews involving CTCL, recall questions, and the records that help establish the timeline.